Metropolis Healthcare's Q3 FY 2025-26 Quarterly Results
- 05 Feb 2026
Result Summary
- Metropolis Healthcare Ltd reported a 3.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 27.5%.
- Its expenses for the quarter were down by 2.9% QoQ and up 23.2% YoY.
- The net profit decreased 20.4% QoQ and increased 33.7% YoY.
- The earnings per share (EPS) of Metropolis Healthcare Ltd stood at 7.94 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 414.93 | 430.08 | 325.32 | -3.5% | 27.5% |
Total Expenses | 348.67 | 359.06 | 282.99 | -2.9% | 23.2% |
Profit Before Tax | 57.16 | 71.03 | 42.34 | -19.5% | 35.0% |
Tax | 15.07 | 18.14 | 10.86 | -16.9% | 38.8% |
Profit After Tax | 42.09 | 52.89 | 31.47 | -20.4% | 33.7% |
Earnings Per Share | 7.94 | 10.13 | 6.09 | -21.6% | 30.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Metropolis Healthcare Ltd is a leading diagnostics company in India, primarily engaged in providing pathology and radiology testing services. As part of the healthcare industry, the company operates a widespread network of testing laboratories and collection centers across the country. Metropolis Healthcare offers a wide range of medical tests and health check-ups, catering to various segments including individual patients, hospitals, and corporate clients. The company has been focusing on expanding its service portfolio and enhancing its technological capabilities. However, specific details on recent major developments for Metropolis Healthcare Ltd are not available within the provided data, and additional research would be necessary to gain insights into any recent strategic initiatives or market expansions.
Revenue
In the third quarter of Fiscal Year 2026 (Q3FY26), Metropolis Healthcare Ltd reported a total income of ₹414.93 crores. This represents a decline of 3.5% quarter-over-quarter (QoQ) compared to ₹430.08 crores in the second quarter of Fiscal Year 2026 (Q2FY26). However, on a year-over-year (YoY) basis, there was a substantial increase of 27.5% from ₹325.32 crores in the third quarter of Fiscal Year 2025 (Q3FY25). This YoY growth indicates a significant expansion in revenue compared to the same period in the previous year. The QoQ reduction in total income could be indicative of seasonal variations or shifts in market demand within the diagnostics industry.
Profitability
For the quarter ending in Q3FY26, Metropolis Healthcare Ltd's profit before tax stood at ₹57.16 crores, showing a decrease of 19.5% QoQ from ₹71.03 crores in Q2FY26. Despite this QoQ decline, the profit before tax increased by 35.0% YoY from ₹42.34 crores in Q3FY25. The company incurred a tax expense of ₹15.07 crores in Q3FY26, which decreased by 16.9% QoQ from ₹18.14 crores in the previous quarter but rose by 38.8% YoY from ₹10.86 crores in Q3FY25. Consequently, the profit after tax for Q3FY26 was ₹42.09 crores, a decrease of 20.4% QoQ from ₹52.89 crores in Q2FY26, yet an increase of 33.7% YoY from ₹31.47 crores in Q3FY25.
Operating Metrics
The earnings per share (EPS) in Q3FY26 were reported at ₹7.94, reflecting a decrease of 21.6% QoQ from ₹10.13 in Q2FY26. However, there was a notable YoY increase of 30.4% compared to ₹6.09 in Q3FY25. This fluctuation in EPS is consistent with the observed changes in profitability metrics. Total expenses for Q3FY26 were ₹348.67 crores, which decreased by 2.9% QoQ from ₹359.06 crores in Q2FY26. On a YoY basis, expenses increased by 23.2% from ₹282.99 crores in Q3FY25. The reduction in quarter-over-quarter expenses, alongside the changes in revenue and profitability, provides a comprehensive view of the company's operational efficiency and cost management over the analyzed periods.